catalyst · primary record
Pasritamig + Docetaxel + Prednisone/Prednisolone
Phase readout · 2027-11-19 · Prostatic Neoplasms, Castration-Resistant
| Company | Janssen Research & Development, LLC |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P3 primary completion · NCT07225946 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:56:19.354Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: Janssen Research & Development, LLC:Pasritamig + Docetaxel + Prednisone/Prednisolone:2027-11-19:P3 primary completion · NCT07225946
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.